ASH 2023 | Combination approaches in AML and overcoming venetoclax resistance
Curtis Lachowiez
• 29 Nov 2023
Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, discusses promising combination approaches for overcoming venetoclax resistance in acute myeloid leukemia (AML). He mentions the excitement surrounding triplet combinations involving IDH1/2 inhibitors, FLT3 inhibitors, and menin inhibitors. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
